#US Benign Prostatic Hyperplasia Procedures Market Growth

[healthcaremarketanalysis]

Leading Urology Devices Manufacturers Driving Innovation in Urological Care

Urology devices play a critical role in diagnosing and treating various urinary tract and male reproductive system conditions. From catheters and stents to advanced robotic surgery systems, these devices offer solutions that improve patient outcomes and enhance healthcare efficiency. With an aging population and the increasing prevalence of urological conditions such as kidney stones, prostate issues, and urinary incontinence, the demand for urology devices is on the rise. Leading manufacturers in the field are meeting this demand through innovation, quality, and a focus on patient-centric solutions.

Download PDF Brochure

Key Players in the Urology Devices Market

Boston Scientific Corporation

A global leader in medical technology, Boston Scientific offers a broad portfolio of urology devices, including products for stone management, prostate health, and bladder control. Their innovations, such as the LithoVue™ Single-Use Digital Flexible Ureteroscope, are transforming how healthcare professionals diagnose and treat urological conditions.

Medtronic

Known for its expertise in medical devices, Medtronic is a prominent player in the urology field with solutions addressing overactive bladder and benign prostatic hyperplasia (BPH). Their minimally invasive therapies, such as the InterStim™ system for bladder control, offer patients more effective, less invasive treatment options.

Coloplast

A major manufacturer of intimate healthcare products, Coloplast is renowned for its urology and continence care solutions. Their product line includes urinary catheters, penile implants, and male incontinence devices, which help patients manage urological conditions with greater dignity and comfort.

Cook Medical

Cook Medical provides a wide range of urological devices, with a strong focus on treating kidney stones, urinary tract obstructions, and bladder dysfunction. The company's flexible ureteroscopes and stent technologies are designed to support urologists in delivering precise, effective treatments.

Olympus Corporation

Olympus is a pioneer in endoscopy, including devices used in urological procedures. Their high-definition imaging systems and minimally invasive surgical tools help physicians perform complex procedures, such as transurethral resection and stone management, with greater accuracy and reduced recovery times.

Request Sample Pages

Technological Advancements in Urology Devices

The urology devices market is experiencing rapid growth due to several technological advancements, including:

Robotic-Assisted Surgery: Systems like the da Vinci Surgical System by Intuitive Surgical allow for more precise urological procedures, improving patient outcomes and reducing recovery time.

Single-Use Devices: The trend towards single-use devices, such as flexible ureteroscopes, eliminates the need for device sterilization, reducing infection risks and improving workflow in clinical settings.

Smart Catheters: These devices can monitor bladder activity and provide real-time data to healthcare professionals, ensuring better management of conditions such as urinary retention.

The Future of Urology Devices

As the prevalence of urological disorders continues to increase, manufacturers are focusing on developing innovative and cost-effective solutions. Companies are also investing in research and development to enhance the safety, efficiency, and comfort of their devices. Minimally invasive surgery, personalized treatments, and smart technologies are key areas where urology device manufacturers will likely continue to make strides.

Conclusion

The urology devices market is expanding rapidly, driven by technological advancements and the increasing prevalence of urological conditions. Manufacturers like Boston Scientific, Medtronic, Coloplast, and Cook Medical are at the forefront of innovation, offering a wide range of devices that improve patient care. As the demand for effective and minimally invasive urological treatments grows, these companies are well-positioned to lead the industry in the coming years.

Content Source:

[mordormr]

Exploring the Bladder Scanners Industry: Trends, Growth Drivers, and Market Outlook

The bladder scanners market size is witnessing significant growth due to the increasing prevalence of urological diseases, technological advancements, and the rising demand for non-invasive diagnostic tools. Bladder scanners, used primarily to measure the amount of urine in the bladder, have become essential in healthcare settings for diagnosing and managing conditions such as urinary retention, bladder dysfunction, and post-operative care. According to recent market research, The bladder scanners market is projected to be valued at USD 159.66 million in 2024 and is expected to grow to USD 214.67 million by 2029, with a compound annual growth rate (CAGR) of 6.10% over the forecast period (2024-2029).

Key Growth Drivers

Rising Prevalence of Urological Disorders: The increasing incidence of urinary tract infections (UTIs), bladder dysfunctions, and other urological disorders is driving the demand for bladder scanners. As the global population ages, conditions such as benign prostatic hyperplasia (BPH) and incontinence are becoming more common, further propelling market growth. Bladder scanners provide a non-invasive solution to accurately assess bladder volume, helping clinicians in early diagnosis and timely intervention.

Technological Advancements: Recent technological innovations in bladder scanner devices have improved their accuracy, ease of use, and portability. Ultrasound-based bladder scanners are increasingly favored for their ability to provide real-time imaging without causing discomfort to the patient. The development of wireless, hand-held bladder scanners with user-friendly interfaces has enhanced their adoption across hospitals, outpatient clinics, and home healthcare settings. These advancements are significantly boosting the market's expansion.

Increasing Awareness and Training in Non-Invasive Procedures: The medical community’s focus on reducing invasive procedures is growing, and bladder scanners are an important part of this shift. With rising awareness about the risks associated with catheterization, healthcare professionals are increasingly adopting bladder scanners as a safer alternative for diagnosing urinary retention. Training initiatives are being conducted to familiarize clinicians with the benefits and usage of bladder scanners, further driving demand.

Rising Demand in Geriatric Care: The aging population is one of the critical growth factors in the bladder scanner market. Older adults are more likely to suffer from conditions such as urinary retention, which requires frequent monitoring. Bladder scanners, which provide quick and accurate readings without the need for invasive procedures, are becoming essential tools in managing geriatric care in both hospital and home-care settings.

Government Support and Healthcare Investments: Governments and healthcare organizations worldwide are investing in improving diagnostic infrastructure, especially in developing countries. Increased healthcare spending and initiatives aimed at improving patient outcomes are likely to contribute to the widespread adoption of bladder scanners. Moreover, regulatory agencies are increasingly focusing on ensuring that diagnostic tools are safe, reliable, and accessible, which is positively impacting the bladder scanner market.

Market Challenges

High Initial Costs: One of the key challenges in the bladder scanner industry is the high initial cost of these devices. While they provide long-term savings by reducing the need for invasive procedures, the upfront expense can be a barrier for smaller clinics and healthcare facilities, particularly in developing regions.

Limited Awareness in Developing Regions: Although bladder scanners offer significant advantages, there is still a lack of awareness in certain regions, especially in rural and underdeveloped areas. Efforts to educate healthcare providers about the benefits of non-invasive diagnostic tools are necessary to expand market penetration in these areas.

Regional Market Dynamics

North America and Europe: Leading the Market North America and Europe are the dominant players in the bladder scanner market, driven by advanced healthcare infrastructure, high prevalence of urological diseases, and strong adoption of innovative medical devices. The presence of leading manufacturers and extensive research and development activities further contribute to the region’s market leadership.

Asia-Pacific: A Rapidly Growing Market: The Asia-Pacific region is expected to witness significant growth in the bladder scanner industry due to the rising aging population, increasing healthcare investments, and growing awareness of bladder health. Countries like China, India, and Japan are experiencing an uptick in demand as healthcare facilities expand their diagnostic capabilities and adopt more advanced technologies.

Conclusion

The bladder scanner market is poised for substantial growth in the coming years, driven by technological advancements, the growing need for non-invasive diagnostic tools, and the rising incidence of urological disorders. As healthcare providers seek more efficient, patient-friendly solutions, bladder scanners are set to play a critical role in improving patient outcomes. With increasing awareness, government support, and ongoing innovation, the bladder scanner industry is expected to expand, creating new opportunities for manufacturers and healthcare institutions alike.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/bladder-scanners-market  

[poonamcmi]

Cyproterone Acetate Market Poised to Grow at a Robust Pace due to Rising Demand for Anti-Androgens

The cyproterone acetate market has witnessed rising demand over the years owing to increasing applications of cyproterone acetate as a powerful anti-androgen. Cyproterone acetate is an anti-androgen steroidal drug that is used for the treatment of hypersexuality or hypersexual disorder, enlarged prostate or benign prostatic hypertrophy, and hirsutism or excessive hair growth in women. It acts by competitively inhibiting androgens like testosterone and dihydrotestosterone from binding to androgen receptors in target tissues.

The Global cyproterone acetate market is estimated to be valued at US$ 327.1 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the cyproterone acetate market are Curia, Axplora, LGM Pharma, Hubei Gedian Humanwell Pharmaceutical, Cipla, NEWCHEM SPA, Swati Spentose, Teva API, Teva Pharmaceutical Industries, Unipex, Zhejiang Xianju Pharmaceutical Co. Ltd, KRKA, Cambrex, Sicor De México, Zhejiang Xianju Xianle, Shaoxing Hantai Pharma, and Farmabios. The key players are engaged in developing improved formulations and delivery methods of cyproterone acetate to increase market share.

The rising prevalence of hormonal disorders like hypersexuality, hirsutism and benign prostatic hyperplasia has opened up opportunities for pharmaceutical manufacturers in the Cyproterone Acetate Market Size Furthermore, increasing awareness about treatment options and availability of generic drugs are fueling the demand.

Technological advancements in drug delivery systems like transdermal patches, gels, and nano-formulations are allowing for better management of hormonal disorders and can drive the adoption of cyproterone acetate.

Market Drivers

A key driver for the cyproterone acetate market is the rising geriatric population who are more prone to benign prostatic hyperplasia. Furthermore, changing lifestyles and increasing stress levels have contributed to the rise in disorders like hypersexuality which is also propelling the demand. Favorable government policies for generic drugs and availability of generic versions of cyproterone acetate at lower costs are facilitating greater market penetration. Challenges in Cyproterone Acetate Market:

Patent Expiry of Acetate Products. Cyproterone Acetate Market  Size And Trends drugs are widely used in the treatment of sex hormone-dependent disorders like precocious puberty, hirsutism and acne, however many patented drugs containing cyproterone acetate are going off patent in the coming years leading to increased competition in the generic market.

Stringent Regulatory Guidelines: Approval processes for new drugs and formulations containing cyproterone acetate are long and stringent. Regulatory authorities like USFDA and EMA impose rigorous evaluation procedures to ensure safety and efficacy. This increases clinical trial timelines and costs.

Potential Side Effects: Cyproterone acetate has few potential side effects if taken for a long duration. Side effects reported include nausea, vomiting, headache, breast tenderness or swelling. Rare side effects include hepatitis, changes in liver function values and blood clotting problems. Potential risks require monitoring and further research on safety.

SWOT Analysis:

Strengths: High growth opportunities in generic drugs market. Well established uses in treatment of hormonal disorders. Weaknesses: Patents expiry of branded drugs. Potential side effects require further safety evaluation. Opportunities: Developing novel drug delivery systems to reduce side effects. Approval of new treatment indications will boost growth. Threats: Stringent regulations delay market approvals. Intense competition from existing and emerging players.

Geographical Regions:

Currently North America accounts for the largest share in cyproterone acetate market, mainly driven by high treatment rates for hormonal disorders. Emergence of new generics and strong reimbursement structure also supports growth. Europe follows North America and holds significant revenue share due to rising healthcare expenditures.

Fastest Growing Region: Asia Pacific region is poised to be the fastest growing market for cyproterone acetate. Increasing patient pool suffering from hormonal imbalance, rising medical tourism, growing healthcare infrastructure and entry of low-cost generics will drive robust growth in Asia Pacific during forecast period. India and China will be the key revenue generators in this region.

Current challenges in Cyproterone Acetate Industry: The cyproterone acetate industry faces challenges from generic competition as major patents expire. Several drugs containing cyproterone acetate as active ingredient lost exclusivity in last few years leading to availability of low-cost generics. This has significantly reduced prices of branded formulations impacting revenues of innovator companies. Another challenge is the stringent regulatory norms for approval of new drugs. The regulatory processes have become complex over time warranting extensive clinical data and trials increasing costs and timelines for industry players. Potential side effects also require further evaluation on long term safety profile through ongoing clinical research. High development costs and regulatory hurdles restrict entry of new market entrants. Overall, generic competition and regulatory challenges are major pain points for cyproterone acetate industry currently. Get More Insights On, Cyproterone Acetate Market For More Insights Discover the Report In language that Resonates with you

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191

[bhushans]

Beyond Diagnosis: Exploring Urology Lasers Market

The Urology Lasers Market is experiencing rapid expansion within the medical industry, driven by cutting-edge laser technologies designed for treating urological conditions. This market's remarkable growth can be attributed to advancements in technology, the integration of telemedicine solutions, and the growing popularity of minimally invasive procedures. These transformative innovations are reshaping urological care, leading to improved precision, better patient outcomes, and increased accessibility to specialized consultations. As the industry continues to evolve, the potential for further advancements promises to revolutionize urology treatments and elevate patient care to new heights.

The market for urology lasers is expected to reach US$ 2.6 Billion in 2033, up from US$ 1.1 Billion in 2023, with a 9.0% CAGR from 2023 to 2033. The global urology lasers market is expected to grow significantly, owing to an increase in the prevalence of urology disorders worldwide and a growing preference for non-invasive surgical procedures.

The urology lasers market is experiencing a significant surge, fueled by remarkable technological advancements and the increasing integration of telemedicine solutions.

These pioneering progressions are revolutionizing the field by enhancing precision, improving patient outcomes, and enabling remote consultations and monitoring.

The market is witnessing a dynamic shift as urologists embrace innovative laser technologies and leverage telemedicine platforms, resulting in improved access to care, streamlined workflows, and expanded treatment options for urological conditions.

The combination of cutting-edge innovations and the growing adoption of telemedicine solutions are propelling the urology lasers market to new heights of growth and transforming the landscape of urological care.

Download The Free Sample PDF https://www.futuremarketinsights.com/reports/sample/rep-gb-17766

Advancements in laser technology have played a pivotal role in transforming urological surgeries. Laser systems offer improved precision, allowing surgeons to target specific tissues and minimize damage to surrounding areas.

The integration of advanced imaging modalities, such as ultrasound and fluoroscopy, further enhances accuracy and enables real-time visualization during procedures.

Laser devices have found applications in multiple urological procedures, including the treatment of kidney stones, benign prostatic hyperplasia (BPH), bladder tumors, and urethral strictures.

The ability to perform minimally invasive surgeries with urology lasers has reduced hospital stays, faster recovery times, and improved patient outcomes. Patients can now benefit from less post-operative pain, minimal scarring, and a quicker return to normal activities.

The urology lasers market is poised for significant growth in the coming years, driven by technological advancements, the rise of minimally invasive surgeries, the increasing prevalence of urological disorders, and the integration of telemedicine solutions.

Key market players are actively investing in research and development activities to enhance the capabilities of urology lasers further and expand their applications. However, challenges such as the high costs of urology laser devices and procedures, safety concerns, and a lack of awareness about laser treatments still need to be addressed.

Collaborations between industry stakeholders, regulatory bodies, and healthcare professionals play a crucial role in overcoming these challenges and unlocking the market's full potential.

Key Takeaways From the Urology Lasers Market:

China is likely to exhibit a CAGR of 8.9% in the urology lasers industry, showcasing strong growth potential.

The market in the United States of America demonstrates robust growth with a CAGR of 9.0% from 2023 to 2033.

The United Kingdom's urology lasers industry is projected to secure a steady CAGR of 8.7% during the projected period.

The benign prostatic hyperplasia segment is likely to secure an 8.8% growth rate from 2023 to 2033.

The holmium laser-type segment is expected to be at the forefront of the market with an 8.9% CAGR from 2023 to 2033.

Top Competition Landscape in the Urology Lasers Industry:

The competition landscape in the urology lasers industry is characterized by intense rivalry among key market players.

Boston Scientific Corporation

Cook Medical Incorporated

Healthtronics, Inc.

Jena Surgical GmbH

Karl Storz GmbH & Co.Kg

Several prominent companies actively engage in research and development activities to introduce innovative urology laser devices and expand their product portfolios.

Strategic collaborations, mergers, and acquisitions are common strategies employed to gain a competitive edge. Furthermore, companies focus on enhancing their market presence through extensive marketing and promotional activities.

With a growing demand for urology lasers, market players strive to establish strong distribution networks, foster partnerships with healthcare facilities, and provide comprehensive customer support and training programs.

Recent Developments in the Urology Lasers Market:

Miniaturization of Laser Devices: Manufacturers have made significant strides in miniaturizing urology lasers, allowing for less invasive procedures and improved patient comfort. The development of compact and portable laser devices has enabled healthcare professionals to perform precise treatments with greater maneuverability.

Advancements in Laser Fiber Technology: Recent innovations in laser fiber technology have led to the development of more efficient and durable fibers. These improved fibers deliver higher energy levels, resulting in enhanced tissue ablation capabilities and reduced procedure times.

Integration of Robotics and AI: The integration of robotics and artificial intelligence (AI) into urology lasers has revolutionized surgical precision and automation. Robotic-assisted laser procedures offer superior accuracy and enable surgeons to perform complex operations with enhanced control and minimal invasiveness.

Telemedicine Solutions: The rise of telemedicine platforms has facilitated remote consultations, preoperative assessments, and postoperative follow-ups. Telemedicine solutions have expanded access to urology specialists and allowed patients in remote areas to receive expert guidance and care.

Segmentation Analysis Of Urology Lasers Market:

By Laser Type:

Holmium

Thulium

Diode

Others

By Application:

Benign Prostatic Hyperplasia

Urolithiasis

Non-Muscle Invasive Bladder Cancer (NMIBC)

Others

Urology Laser Market

[mrfr-blogs]

Navigating the Dynamics of Urology Devices Market Industry

Market Overview –

The Urology Devices Market encompasses medical devices and equipment used in the diagnosis, treatment, and management of urological disorders and conditions affecting the urinary tract and male reproductive system. This includes devices for urinary incontinence, kidney stones, benign prostatic hyperplasia (BPH), urinary tract infections (UTIs), erectile dysfunction, and other urological conditions.

One significant driver of the Urology Devices Market's growth is the increasing prevalence of urological disorders worldwide, driven by factors such as aging demographics, lifestyle changes, and the rising incidence of chronic diseases such as diabetes and hypertension. As the population ages, the demand for urology devices for conditions such as urinary incontinence, BPH, and kidney stones is expected to rise.

Advancements in urological procedures and minimally invasive surgical techniques have also fueled market growth by expanding the scope of treatment options available to patients. Urology devices such as catheters, stents, lithotripters, and robotic surgical systems enable healthcare providers to perform complex procedures with greater precision, reduced recovery times, and improved patient outcomes.

Moreover, the increasing awareness of urological health and the availability of advanced diagnostic and treatment options have led to greater patient demand for urology devices and services. As healthcare systems prioritize preventive care and early intervention, the Urology Devices Market is expected to continue growing, offering opportunities for innovation and investment in medical device technology.

The Urology Devices Market is witnessing steady growth, driven by rising urological disorders and technological advancements in medical devices. Urology devices such as catheters, stents, and endoscopes are vital in diagnosing and treating urinary tract conditions. With a growing aging population and increasing awareness, the demand for urology devices continues to escalate.

The urological devices market was valued at USD 36.5 billion in 2022 and is expected to rise from USD 37.96 billion in 2023 to USD 48.5 billion by 2032, with a compound annual growth rate (CAGR) of 4% between 2023 and 2032.

Market Segmentation –

The global Urology Devices market has been segmented based on Type, Application, Technology and End-User.

On the basis of Type, the market is segmented into dialysis equipment, urinary stone treatment devices, endoscopy devices, benign prostatic hyperplasia treatment devices, and urinary incontinence & pelvic organ prolapse. The market revenue for urology devices was dominated by endoscopic devices in 2022, which can be ascribed to the rising prevalence of urolithiasis and the strong demand for disposable cystoscopes, particularly in developed nations.

Based on Application, the global Urology Devices market has been segmented into Minimally Invasive Surgery and Robotic Surgery. In 2022, the minimally invasive surgery category dominated the industry. According to projections, the terminal side segment will experience the largest growth between 2023 and 2030, with an increase in urological problem patients choosing minimally invasive procedures over more invasive ones.

Based on Technology, the global Urology Devices market has been segmented into benign prostatic hyperplasia, prostate cancer, urinary stones, and urinary incontinence. Due to the higher risk of developing urine incontinence in diabetic patients, the urinary incontinence Urology Devices category had the majority share of the market revenue for Urology Devices in 2022.

Based on End-User, the global Urology Devices market has been segmented into hospitals and ambulatory services. Due to the increasing number of patient visits at hospitals for urology-related illnesses, the hospitals and clinics segment, which held the market's top spot in 2022, is anticipated to grow at the fastest rate throughout the forecast period, 2023-2030.

Regional Analysis –

The regional analysis of the urology devices market reveals varying dynamics influenced by factors such as healthcare infrastructure development, prevalence of urological disorders, and regulatory frameworks. North America dominates the market, driven by the high prevalence of conditions like urinary incontinence and kidney stones, coupled with advanced medical technology adoption. Europe follows suit, with increasing investments in urology devices and rising demand for minimally invasive procedures. In the Asia-Pacific region, improving access to healthcare services, growing aging population, and increasing awareness about urological health contribute to market growth. Developing regions in Latin America and Africa are also witnessing gradual market expansion as healthcare infrastructure improves and awareness about urological disorders increases.

Key Players –

Urology devices companies include KARL STORZ GmbH & Co. KG, Olympus Corporation, Medtronic, Boston Scientific Corporation, R. Bard, Fresenius Medical Care AG & Co. KGaA (Germany), Dornier MedTech (Germany), and Stryker (US)

Related Reports –

US Melanoma

Middle East and Africa HIV Diagnosis & Treatment

Gastroparesis Treatment

Dental Infection Treatment

For more information visit at MarketResearchFuture

[blog-site-for-market-research]

Urology Devices Market Size, Share, Trends, and Growth Opportunity Analysis

Market Scope

The urology devices market size was valued at USD 36.5 billion in 2022 and is expected to rise from USD 37.96 billion in 2023 to USD 48.5 billion by 2032, with a compound annual growth rate (CAGR) of 4% between 2023 and 2032.

Growth Drivers and Challenges

Notable rise in the number of patients suffering from diabetes and high blood pressure (hypertension) has fostered the demand for advanced urology devices in recent years. These diseases are known for causing kidney failure. The American Kidney Fund’s recent studies show that nearly 40.4% of the overall kidney failure cases worldwide are caused by diabetes, while 30% is the result of high blood pressure. Cases of diabetes and hypertension have been surging exponentially in developing countries across Middle East and Asia Pacific, considering the prevalence of stressful and hectic lifestyle and the burgeoning elderly populace.

Another growth rendering factor can be the expanding geriatric population prone to kidney and urinary disorders. The demand for urology devices is further elevated by the mounting demand for minimally invasive procedures and surge in technical advances. Canada as well as the United States (US) are experiencing substantial rise in the number of people affected by chronic kidney and urinary disorders in conjunction with the growing prevalence of a sedentary lifestyle. On top of this, large-scale funds by governments for improving the healthcare infrastructure would also have an incredible impact on the global market.

Market Segmentation

The MRFR study has outlined various aspects of the urology devices industry for enhanced understanding, shedding light on major segments like types, applications, technology, and end users.

Different types of urology devices available in the industry are endoscopy devices, urinary incontinence & pelvic organ prolapsed devices, urinary stone treatment devices, benign prostatic hyperplasia treatment devices, dialysis equipment, and more.

Urology devices’ top applications are Prostate Cancer, Urinary Incontinence, Urinary Stones, as well as Benign Prostatic Hyperplasia. Urinary stones occur in 1 in every 20 individuals, with the major reasons being diabetes, high blood pressure, and history of kidney failure. As a result, urology devices market trends are witnessing enormous demand for treating urinary stones, cases of which have been escalating rapidly worldwide.

Technology-wise, the segments are minimally invasive surgery, robotic surgery, and more.  

End-users listed are ambulatory services, hospitals, and more.

Regional Analysis

The urology devices industry has been regionally considered for APAC/Asia Pacific, MEA/Middle East & Africa, the Americas, and Europe.

America maintains its winning streak and will continue to do so throughout the evaluation timeframe, thanks to the escalating cases of kidney stones, traumatic injury, prostate cancer, and others. The American Urological Association Foundation confirms that benign prostatic hyperplasia (BPH), urinary incontinence (UI), urinary tract infections, and kidney and ureteral stones are the top urological ailments occurring in the region. Surge in lifestyle-based health issues, significant healthcare spending, and a well-developed healthcare system present in both Canada and the US also add to the regional market value. Favorable reimbursement structure also add to the market worth. Not only clinics and hospitals, but urology devices are increasingly being used in the domestic sector as well, as the rising number of geriatric patients prefer at-home settings.

Asia Pacific could be the fastest progressing market in the next few years, on account of the booming population with significant unmet medical needs and the surge in economic standards. Mounting cases of Benign Prostatic Hyperplasia (BPH) as well as Urinary Tract Infection (UTI) also raises the demand for urology devices. With the rising focus on replacing and upgrading the existing healthcare infrastructure, urology devices would note higher demand in the following years. Besides, majority of the players in the region are spending considerably on exhaustive research and development of the latest types of urology devices. Urology device manufacturers are also indulging in mergers and acquisitions to enhance individual as well as cumulative industry growth.

Top Companies

The top urology devices manufacturers in the market are C. R. Bard Inc. (US), Boston Scientific Corporation (US), Stryker (US), Olympus Corporation (Japan), HealthTronics, Inc (US), KARL STORZ GmbH & Co. KG (Germany), NIKKISO CO. LTD (Japan), Medtronic (US), Dornier MedTech (Germany), Fresenius Medical Care AG & Co. KGaA (Germany), Cook (US), and many more.

These contenders expend huge amounts on research and development (R&D) for product innovation as well as new launches, which helps them gain a higher share in the worldwide industry. They also use strategies such as acquisitions, FDA approvals, collaborations, expansions, and joint ventures, among others.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[techninja]

Redefining Pain Management: Radiofrequency Ablation Device Market on the Rise

Introduction

The Radiofrequency Ablation Device Market has witnessed remarkable growth in recent years due to its effectiveness in treating various medical conditions, ranging from chronic pain management to oncological interventions. Radiofrequency ablation (RFA) is a minimally invasive procedure that uses high-frequency electrical currents to heat and destroy abnormal tissues or nerves, offering patients a safer and less invasive alternative to surgery. This article explores the current landscape and emerging trends in the Radiofrequency Ablation Device Market.

Market Overview

The global Radiofrequency Ablation Device Market has been expanding steadily, driven by increasing awareness among both patients and healthcare professionals about the benefits of RFA procedures. Chronic pain management remains one of the primary applications of radiofrequency ablation, with an aging population and rising prevalence of chronic pain conditions contributing to market growth.

Key Trends in the Radiofrequency Ablation Device Market

1. Advancements in Technology: The Radiofrequency Ablation Device Market is witnessing continuous technological advancements. Manufacturers are developing innovative devices with improved precision and safety features. The integration of advanced imaging technologies like real-time ultrasound and MRI guidance has increased the accuracy of RFA procedures, making them more effective.

2. Expanding Indications: Radiofrequency ablation is no longer limited to pain management. The market is witnessing an expansion in the range of clinical indications, including the treatment of cardiac arrhythmias, liver tumors, and benign prostatic hyperplasia. This diversification of applications is opening up new opportunities for device manufacturers.

3. Growing Geriatric Population: With the global aging population, the demand for minimally invasive treatment options is on the rise. Elderly individuals are more prone to conditions such as osteoarthritis and back pain, making RFA an attractive option. This demographic shift is a significant driver of market growth.

4. Outpatient Settings: The trend toward outpatient and office-based medical procedures has accelerated due to the COVID-19 pandemic. Radiofrequency ablation, with its minimally invasive nature and reduced recovery time, fits well into this trend. More RFA procedures are now being performed outside traditional hospital settings.

5. Rising Adoption of RFA for Cancer Treatment: Radiofrequency ablation is increasingly being used as an alternative or adjunct therapy for certain types of cancer. It is particularly effective for patients who are not suitable candidates for surgery. The market is witnessing increasing interest in RFA devices for oncological applications.

6. Regulatory Advancements: Regulatory bodies are actively involved in streamlining and expediting the approval process for radiofrequency ablation devices. This is promoting innovation and ensuring that safe and effective devices reach the market faster.

7. Market Consolidation: The Radiofrequency Ablation Device Market has been witnessing consolidation as larger healthcare companies acquire smaller manufacturers. This consolidation is often aimed at expanding product portfolios and gaining a competitive edge in the market.

8. Patient-Centric Approach: Patients are becoming more proactive in their healthcare decisions. This shift towards a patient-centric approach is driving the demand for minimally invasive procedures like RFA, as patients seek treatments that offer shorter recovery times and reduced side effects.

Conclusion

The Radiofrequency Ablation Device Market is poised for continued growth in the coming years. Advancements in technology, a broader range of clinical applications, and the aging global population are among the primary factors driving this growth. As the market continues to evolve, it is expected that radiofrequency ablation will become an even more integral part of modern medical practice, offering patients effective and minimally invasive treatment options for a wide range of medical conditions.

[pharmaceuticalsindustrynews]

Low-Cost and High Insurance Coverage Set to Make UroLift Procedure Most Popular Benign Prostatic Hyperplasia (BPH) Treatment Option in U.S. in Future

Benign Prostatic Hyperplasia (BPH) is a medical condition in which the prostate gland becomes enlarged. The enlargement of the prostate gland causes urinary tract problems by blocking the flow of urine out of the body. This happens because the prostate gland surrounds the urethra, which is the tube that carries the urine from the urinary bladder to out of the body, and so, the enlargement of the gland squeezes or blocks the urethra, causing discomfort and problems while urinating. 

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

This condition is common in geriatric men, so much so, that almost half of all men in the age bracket 51—60 years suffer from it. As per many studies and reports, up to 90% of all men over the age of 80 years all over the world suffer from benign prostatic hyperplasia. This disease is commonly treated via medications, laser-based treatment, transurethral resection of the prostate (TURP), and various other energy-based treatments such as prostate artery embolization and implants.

Make an Enquiry before Purchase: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

Out of the surgical, laser-based, and UroLift procedures, the requirement for UroLift treatment procedures is predicted to rise rapidly in the U.S. in the forthcoming years. The main factors responsible for the growing popularity of these treatment procedures are the increasing aging population, lower-costs of the procedure in comparison to the other energy-based procedures, and increasing provision of insurance coverage for this procedure by many insurance companies in the country.

Out of these, the demand for green light laser-based procedures was observed to be significantly high in the U.S. during the last few years. According to many experts, the main factor responsible for the large-scale adoption of green light laser-based procedures was the fact that these procedures allow faster recovery and cause far lesser short-term side effects in comparison to the other laser-based procedures. Moreover, these procedures significantly improve the comfort level experienced by patients while urinating.

[fridgedirt03]

Mk 2866 Ostarine Adverse Effects, Advantages & Dose Testimonial 2021

Best Sarms To Pile With Lgd 4033, Finest Sarms Gains

Content

Where Did Sarms Come From?

For Endurance Efficiency: Cardarine + Execute Package.

Ligandrol.

Usn Pure Protein Gf.

Different Types Of Sarms & What They Do.

Article cycle treatment is extremely recommended for LGD-4033 users as it is an exceptionally potent medicine and you should always get on the more secure side by adhering to a carefully-planned PCT. Additionally, you must just purchase ideal Ligandrol from premier SARMs UK store-- The SARMs Store. Ligandrol individuals can expect a leaner look at the end of their LGD-4033 cycle if they follow a tidy and also stringent diet regimen while bulking. They can additionally expect denser as well as fuller muscle mass along with considerable renovations in the degrees of vascularity. Some individuals experience even more dry or damp gains than others but nothing on the severe side.

direct-peptides.com: Vial shop Peptides online: a blog article ='text-align:center'>

On-cycle support with the Bodybuilt Labs SARMs Cycle Support 90 Capsules and also Blog post cycle treatment with the Bodybuilt Labs SARMs PCT 90 Capsules is very suggested during and after an LGD-4033 cycle. Ideally, the suggested dosage of Ligandrol for guys is 5-10mg on a daily basis in a cycle of 8 to twelve weeks. For females, the advised dose of Anabolicum is 2.5-5mg daily. Ligandrol is finest piled with Nutrabol as a result of their synergistic results in a bulking cycle.

Where Did Build Muscle shop Peptides online Come From?

This pile is likewise helpful to construct muscle dimension and mass while improving the sense of health, recovery, and the quality of rest. LGD-4033 is a lot more powerful and also powerful than various other careful androgen receptor modulators. You can certainly anticipate to pack on even more muscular tissue mass as well as dimension utilizing LGD-4033 than you can ever before with Andarine as well as Ostarine.

It has actually also been revealed to be a lot more anabolic than testosterone, as well.

Over the last few years, steroid usage has been expanding throughout the UK - not only amongst gym-goers and also bodybuilders, as you would anticipate, however in certain expert areas, as well.

RAD is powerful sufficient to restrict the effect of testosterone on the prostate and also other undesirable areas.

Cardarine supplements likewise regulate the various proteins that the body makes use of for energy.

Dosing seems in the 4mg to 12mg variety, with ideal cycle size being 4 to 6 weeks.

Over the span of 8 to 12 weeks, you can anticipate 8-10 extra pounds of solid and clean muscular tissue provided you are eating correctly as well as training like a Hulk. The majority of LGD-4033 have reported that they were able to gain 1 extra pound a week by just eating calories over upkeep. Some users also reported that they had the ability to experience the same gains even without raising their calorie consumption.

For Endurance Performance: Cardarine + Do Package.

This is where a combination of Ostarine as well as Andarine fit the better than LGD-4033 and even RAD-140 for a reducing cycle. You can anticipate impressive outcomes during SARMs bulking cycles with LGD-4033 than you would certainly with RAD-140, MK-2866, and S-4. A discerning androgen receptor modulator, LGD is among the most powerful efficiency enhancing medicines in today's bodybuilding market. Terms and Conditions Peptides India is a non-peptidic, by mouth energetic and selective agonist of the development hormonal agent secretagogue (secretion-boosting) receptor. It imitates the activity of ghrelin in the tummy, elevating growth hormone as well as IGF-1 degrees, yet does not influence cortisol degrees. The optimal cycle size for guys is eight to twelve weeks while the excellent cycle length for females is 6 to 8 weeks. Article cycle therapy of four weeks is very suggested after an LGD-4033 cycle.

LGD-4033 is effective to produce all of the amazing restorative advantages of testosterone with a significantly boosted safety account. This is due to its dental path of administration and the tissue-selective mechanism of activity. Ligandrol is additionally qualified by a high degree of bioavailability that implies it can be orally dosed in contrast to calling for intramuscular shot. LGD-4033 does not call for methylation to get absorbed and made use of in the body as compared to oral steroids. Anabolic steroids are purposefully developed with a methyl or ethyl team, at the C17α position and therefore confirms liver toxic. Recomposition would certainly be the best foot onward for you if you are looking for just testing the waters with LGD-4033. All you need is to keep the calories under maintenance as well as take pleasure in an excellent as well as tidy diet plan and then leave no stone unturned when it comes to hitting the gym hard.

Ligandrol.

Moreover, the benefits brought by Ligandrol don't obtain stained because of negative effects like prostate enlargement, hypertension, or organ strain. This compound also does not cause gynecomastia, hair loss, and prolactin production that are so frequently related to anabolic androgenic steroids as well as prohormones. Ligandrol is likewise valuable to stay clear of the typical side effects connected with steroids and also prohormones like prostate carcinoma, acne breakouts, male pattern baldness, and also benign prostate hyperplasia.

A Better Body in a Pill? Experts Urge Caution on SARMs - The New York Times

A Better Body in a Pill? Experts Urge Caution on SARMs.

Posted: Thu, 12 Apr 2018 07:00:00 GMT [source]

The best thing is that LGD-4033 while being safe still creates outstanding results which is a substantial selling point in itself. For this, you can attempt piling Ligandrol with S-4 and also you can anticipate enhanced muscle size and constant fat loss over a duration of eight to twelve weeks. However, you should constantly bear in mind that the LGD-4033 cycle results will predominantly depend upon your training as well as diet regimen program. You must likewise make it an indicate stay hydrated throughout the day and also take pleasure in great, top quality, and also continuous rest throughout the duration of your Ligandrol reducing cycle. For reducing, Ostarine and also Andarine with each other are much better alternatives. This is simply because it does not make good sense to utilize a compound that is incredibly powerful when reducing. The most important thing that you must always keep in mind is that you ought to just be caring for an anabolic agent that has the possible to counter muscular tissue wasting, particularly when you are at a severe calorie shortage.

Usn Pure Protein Gf.

Nevertheless, Ligandrol is not that ideal when it involves reducing stubborn fat though it does have the ability to thaw fat off. Nonetheless, you ought to never overlook the significance of post cycle treatment after an LGD-4033 cycle. This will certainly aid you considerably as Ligandrol firstly does not closed down the natural manufacturing of testosterone as significantly as anabolic androgenic steroids. Second of all, your trip of natural testosterone healing will certainly be much easier and also quicker as long as you beware with the appropriate on-cycle support and correct message cycle therapy procedure. The androgen receptor selectivity of LGD-4033 maximises anabolic effects while the SARM also demonstrates effectiveness to enhance the joints that consequently stops injuries. One of the notable benefits of Ligandrol is that it does not trigger aromatisation that means you don't need to ever before worry about a remarkable rise in estrogen levels.

[healthcaremarketanalysis]

Urology Devices Market worth $48.6 billion by 2028

Urology Devices Market in terms of revenue was estimated to be worth $34.1 billion in 2023 and is poised to reach $48.6 billion by 2028, growing at a CAGR of 7.3% from 2023 to 2028 according to a new report by MarketsandMarkets. The high prevalence of urological diseases significantly impacts the increased demand for urological devices. Cancer patients who need surgical interventions with latest technologies like minimally invasive surgery and robotic surgeries. This will lead to an increased need for urological devices. Thus, the escalating demand for urological disease diagnosis and treatment, has led to a pressing need for technologically advanced devices, which is thereby expected to support the growth of the urological devices market.

Download an Illustrative overview:

Browse in-depth TOC on "Urology Devices Market"

159 - Tables

44 - Figures

274 – Pages

In 2022, the instruments segment held the largest share of the urology devices market by product segment.

The urology devices market is segmented into instruments and consumables & accessories based on products. The instruments segment accounted for the largest share of the urology devices market in 2022. This segment covers the most commonly used products, such as dialysis devices, endoscopes, laser & lithotripsy devices, endovision & imaging systems, robotic systems, insufflators, endoscopy fluid management systems, urodynamic systems and other instruments. These products are commonly used in hospitals, dialysis centers and home care settings. As technologies continue to evolve, the efficiency and accuracy of these products contribute significantly to the urological procedures.

The kidney diseases segment held the largest share of the urology devices market by application segment in 2022.

The global urology devices market is differentiated into kidney diseases, urological cancer, pelvic organ prolapse, benign prostatic hyperplasia, urinary incontinence, erectile dysfunction, urinary stones and other applications. In 2022, the kidney diseases segment dominated the urology devices market. The urology devices market in kidney diseases is expected to grow at a high rate owing to the rising incidence of kidney diseases and chronic diseases. With a burgeoning global population, the need for urology devices has significantly increased due to the increased number of procedures required. Hospitals and dialysis centers are at the forefront of this surge, as they cater to routine medical care and handle emergencies.

The hospitals, ASCA & clinics segment held the largest share of the urology devices market by end-user segment in 2022.

The global urology devices market is differentiated into hospitals, ASCS & clinics, dialysis centers and home care settings. In 2022, the hospitals, ASCS & clinics segment dominated the urology devices market. The urology devices market in hospitals is expected to grow at a high rate owing to the increasing number of surgical procedures related to urology care. The expanding network of healthcare institutions directly translates to a substantial market share, reflecting the pivotal role hospitals play in safeguarding patient well-being.

North America is the largest regional market for urology devices market.

The market for urology devices has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the predominant portion of the urology devices market. This can be attributed to the region's advanced healthcare facilities and substantial healthcare investments, which are pivotal in fueling the requirement for urology devices. Moreover, the projected rise in urological procedures is anticipated to contribute to the expansion of the market. As the demand for urological procedures rises, so does the need for precise urological devices to ensure successful and safe procedures.

Request Sample Pages:

Urology Devices Market Dynamics:

Drivers:

Rising incidence of urological diseases

Growing preference for minimally invasive procedures

Rising focus on R&D and product launches

Growing number of hospitals and surgical centers

Restraints:

High degree of consolidation among key players

Opportunities:

Growing Potential growth opportunities in emerging economies

Technological advancements

Challenge:

Increasing number of product recalls by key players

Shortage of skilled urologists

Key Market Players of Urology Devices Industry:

The major players operating in urology devices market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International, Inc. (US), Boston Scientific Corporation (US), Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), Cardinal Health (US), Olympus Corporation (Japan), Intuitive Surgical (US), Coloplast A/S (Denmark), Stryker Corporation (US), Teleflex Incorporated (US), Convatec Group PLC (UK), Medtronic PLC (Ireland), Karl Storz (Germany), Cook Medical (US), Richard Wolf GmbH (Germany), CompactCath (US), Dornier MedTech (Germany), Nikkiso Co., Ltd. (Japan), Dialife SA (Switzerland), Erbe Vision (Germany), Well Lead Medical Co., Ltd. (China), ROCAMED (Germany), EndoMed Systems GmbH (Germany), Amniso International, Inc. (US), Medispec (US), Medical Technologies of Georgia (US), Vimex Sp. z o.o. (Poland), Balton Sp. z o.o. (Poland), Hunter Urology (UK), Ribbel International Ltd. (India).

Recent Developments of Urology Devices Industry

In August 2023, Fresenius Medical Care AG & Co. KGaA (Germany), announced FDA Clearance for the product Versi HD with GuideMe Software.

In December 2022, Boston Scientific Corporation (US) and Acotec Scientific Holdings Limited (China) announced today that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures.

In May 2022, B. Braun SE (Germany) entered into a distribution agreement, and B. Braun surgery division Aesculap has strengthened its long-term partnership with True Digital Surgery, a Californian company that is an expert in robotically controlled 3D digital visualization.

In April 2022, Baxter International, Inc. (US) Announces U.S. FDA Clearance of ST Set used for renal replacement therapy (CRRT)

In April 2021, Becton, Dickinson and Company (US) announced an investment of USD 65 million for the construction of a state-of-the-art medical facility in Tucson, Arizona (US), which will serve as a final stage manufacturing and sterilization center to improve overall efficiency, customer service, and supply chain in the US.

Urology Devices Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall urology devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence of urological diseases, growing preference for minimally invasive procedures, rising focus on R&D and product launches, growing number of hospitals and surgical centers), restraints (high degree of consolidation among key players), opportunities (potential growth opportunities in emerging economies, technological advancements) and challenges (increasing number of product recalls by key players, shortage of skilled urologists) influencing the growth of the urology devices market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the urology devices market.

Market Development: Comprehensive information about lucrative markets – the report analyses the urology devices market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the urology devices market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International, Inc. (US), Boston Scientific Corporation (US), Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), among others in the urology devices market strategies.

[healthcare-domain]

Prostate Health Market Size, Share | 2022 – 2026 | MarketsandMarkets

The global prostate health market is projected to reach $48.9 billion by 2026, Provides crucial industry insights that will help your business grow. Growth in this market is primarily driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in prostate health, increase in prevalence of prostate cancer, surge in demand for hormone therapy drugs, emerging therapies for prostate cancer and increasing incidence of prostatitis.

The prostate health market witnessed a loss of business, and the trend continued till late December 2020. Unfavorable changes in regulations and guidelines are hindering the growth of this industry.

Major regulatory authorities across the globe (such as CDC, WHO, MHRA, TGA, and EMA) have identified that cancer patients are at greater risk of contracting the coronavirus infection than healthy adults. Thus, prostate care, diagnostic tests, and surgical treatments in hospitals are severely restricted or postponed at hospitals and cancer care centers. This is expected to cause disturbances in the prostate health market. Owing to the factors above, caregivers and hospitals are anticipated to witness delays in elective surgeries and screening procedures.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107055093

However, the market has gradually increased from the second half of 2020 due to the rise in the number of oncology appointments, prostate cancer therapies among others resulting from efforts to clear backlogs and new cases and fully re-opened healthcare services.

Data from the Health Insurance Review and Assessment (HIRA) agency in 2018 showed that nearly 7,600,000 patients were diagnosed with BPH in 2010, which increased by ~1.2 million in 2017. This represents an annual growth of about 7% and a total increase of 58% from 2010.

Obesity and Benign Prostatic Hyperplasia (BPH) are closely associated. According to the Journal of Global Health Reports published in 2019, nearly 37.1% of men aged 60 years and older in the US were classified as obese. Studies reveal that the prevalence of obesity generally increases among men with progressing age, leading to BPH. Obesity leads to several mechanisms such as enhanced sympathetic nervous activity, altered endocrine status, increased intra-abdominal pressure, increased inflammation process, and oxidative stress, which are favorable conditions for the development of BPH.

The prevalence of prostate cancer rises with an increase in age. Prostate cancer is the most common category of cancer among men. According to the American Cancer Society’s estimates for prostate cancer in 2021, about 248,530 new cases and 34,130 deaths occurred in 2020 due to prostate cancer in the US.

The prostate cancer phase III pipeline is diverse and comprises molecules in approved drug classes as well as drugs with novel mechanisms of action, including radioligands targeted to prostate-specific membrane antigen (PSMA), kinase inhibitors, and immune checkpoint inhibitors.

[isucheta]

Increase in Prevalence of Benign Prostatic Hyperplasia along with Growing Risk Factors to Drive Global Benign Prostatic Hyperplasic Devices Market

According to our new research study on "Benign Prostatic Hyperplasic Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Procedure Type, End User, and Geography" the market is expected to grow from US$ 2,078.78 million in 2021 to US$ 3,467.31 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

The report highlights the key factors driving the market and prominent players with their developments. The growth of the benign prostatic hyperplasic devices market is primarily attributed to the rise in the prevalence of benign prostatic hyperplasia among men, increasing risk factors, and a rise in investments, funds, and grants for research in BPH treatment. However, less awareness about prostate health among men is hampering the market's growth to a certain extent.

Get Sample PDF at:- https://www.theinsightpartners.com/sample/TIPRE00025704/

Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate. BPH is a non-cancerous prostate condition that is not usually fatal. As it is  benign, the condition does not involve metastasis to other body parts. BPH is not associated with the risk of prostate cancer; moreover, unless it manifests symptoms, BPH is not considered a health issue. Almost all men are likely to have some prostate growth by age 70. Aging, abdominal obesity, and lack of physical exercise raise the risk of developing BPH.

The companies engaging in the benign prostatic hyperplasic devices market witnessed a negative impact on their services in early 2020 due to the temporary shutdown of their manufacturing sites caused by the COVID-19 pandemic. Most service providers prioritized actions to help the critical work of consumers included in COVID-19, such as giving a range of high-quality COVID-19-related research tools, reassigning R&D resources for producing essential products for COVID-19, expanding the supply chain, providing flexibility to support expanded demand for enduring products applied for COVID-19 research, and entering into discussions and collaborations across the UK, the US, and China concentrated on SARS-CoV-2 diagnostics, drugs, and vaccines development. Surgical procedures such as TURP, HoLEP, ThuLEP, and PVP were postponed because of COVID-19. According to a recent study, nearly 2.5 million urological benign surgeries were estimated to be canceled during the peak of disruption by COVID-19. However, the number of alternative surgical procedures increased. For instance, laser treatment can be adopted by additional surgery centers and other outpatient facilities not focused on COVID-19 patients.

The report segments the benign prostatic hyperplasic devices market as follows:

Based on product, the benign prostatic hyperplasic devices market is segmented into resectoscopes, urology laser, radiofrequency ablation devices, prostatic stents, and implants. Based on procedure type, the market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. By geography, the benign prostatic hyperplasic devices market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

About The Insight Partners

The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in industries such as healthcare, media, and telecommunication.

Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.

Our research content is majorly focused toward market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, product and service, radioisotope types, application and end user, which helps our clients to gain a deeper analytical understanding of various research topics.

Contact Us

If you have any queries about this report or if you would like further information, please contact us:

North America: +1 646 491 9876

Asia Pacific: +91 20 6727 8686

Email: sales@theinsightpartners.com

[marketresearchindia]

Global Machine Vision In Mobile Devices Market Growth Is Propelled By Growing Investments In R&D Activities: Ken Research

Buy Now

A urinary catheter is a hollow, incompletely flexible tube, which is utilized to drain urine when an individual is powerless to do it naturally. The urinary self-catheter industry is projected to experience proficient growth during the review period, due to increment in requirement for hydrophilic intermittent catheter across geographies. Growth in number of prostate surgeries; augment in prevalence of benign prostate hyperplasia, urinary incontinence, and spinal cord injuries; augment in geriatric population, and employment of favourable reimbursement policies for utilization of intermittent catheter further boost the growth of urinary self-catheters market.  

According to the report analysis, ‘Global Urinary Self Catheter Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027’ states that B. Braun, Bard Medical, Coloplast, Medtronic, Med Tech GA, Hollister, Teleflex, ASID BONZ GmbH, ConvaTec, Cook Medical and many more are the foremost companies which presently working in the global urinary self catheter market more proficiently for keep maintaining the governing position, registering the great value of market share, obtaining the competitive edge, leading the highest market growth and generating the highest percentage of revenue by analysing the strategies and policies of government as well as contenders, spreading the awareness connected to the applications and advantages of urinary self catheter, decreasing the associated prices of such, delivering the better customer satisfaction, increasing the features and benefits of urinary self catheter, improving the qualitative and quantitative measures of such, implementing the policies of profit making and strategies of expansion, and analysing the strategies and policies of government as well as contenders.

The urinary self catheters market is predicted to observe lucrative growth opportunities over the forecast duration, owing to speedy healthcare improvements, augment in geriatric population, and enhanced healthcare infrastructure. Technological innovations and favorable reimbursement policies in the healthcare sector assist the market expansion. Bladder catheterization is the most commonly executed process in hospitals, which propels the urinary catheters market. The effective growth in prevalence of prostate cancers and surging prostate functions in hospitals requirement for urinary catheters on a constant basis.

Request For Sample Report-https://kenresearch.com/sample-report.php?Frmdetails=NDQ0OTAw

North America shows profitable growth opportunities in the urinary self-catheters market due to growing geriatric population, innovations in the healthcare industry, and augmenting the number of surgical procedures. Advancements in healthcare facilities and growing investments in R&D activities in urinary catheters are propelling the expansion of the global market. North America is registering the urinary self catheters market due to its speedily developing healthcare infrastructure and awareness of urinary catheters. Market contributors from North America are aiming on adopting several strategies to strengthen their market existence.

Also, regulatory policies in Asia Pacific are more adaptive and business-friendly than those in developed regions. This, along with the growing competition in mature markets, has induced foremost players in the urinary self catheters market to aim on emerging economies. Therefore, it is predicted that during the near period the market of urinary self catheter will augment more proficiently over the assess period.

For More Details-

Global Urinary Self Catheter Market Research Report

Related Post-

2021-2027 Global and Regional Infusion Pump Industry Status and Prospects Professional Market Research Report Standard Version

2021-2027 Global and Regional ECHO Cardiography Industry Status and Prospects Professional Market Research Report Standard Version

Follow Us

LinkedIn | Instagram | Facebook | Twitter | YouTube

Contact Us:-

Ken Research                                                                                          

Ankur Gupta, Head Marketing & Communications

support@kenresearch.com

+91-9015378249

[jainm24]

Urinary Catheters Market  Share, Industry Growth, Trend, Key Companies by 2030

The urinary catheter sizes market size is expected to reach USD 3.38 Billion in 2030 and register a revenue CAGR of 5.4% over the forecast period, according to the latest report by Reports and Data. Increasing demand for minimally invasive surgical procedures and rising incidences of Benign Prostatic Hyperplasia (BPH) are factors driving revenue growth of global urinary catheter market.

Advancements in the healthcare sector have introduced modern medical devices that have revolutionized medical treatments, which improved the quality of life of people suffering from lifestyle and chronic diseases. A catheter is a tube that is inserted into the body through a narrow opening or surgically placed inside the body which can be used for several functions. Geriatric population always suffers from urinary retention and urinary incontinence problems, which is boosting market revenue growth. In the US more than 30 million urinary catheter sizes are sold annually and the catheterization rate in non-intensive care units is more than 20% and in an ICU is 60%. urinary catheter sizes are commonly used in patients with incontinence, spinal cord injury, neurogenic bladder, and urine flow obstruction.

Moreover, growing demand for minimally invasive procedures owing to less postoperative pain, shortened hospital stay, faster recovery times, and less scarring are opening new dimensions for the use of urinary catheter sizes.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2514

Some Key Factors Contributing to the Global Pharma & Healthcare Market Growth

Unprecedented revenue growth of the global pharma & healthcare industry is attributed to factors such as rising prevalence of chronic and acute diseases worldwide, increasing geriatric population, rising awareness of health & wellness among consumers, and growing demand for more advanced healthcare services. Increasing demand for advanced drugs and therapeutics, growing availability of next-generation diagnostics and treatment options – especially in developing countries like India and China – rise in R&D activities and clinical trials in the pharmaceutical and biotechnology sectors, increasing public and private investments in healthcare research projects, and rising consumer expenditure on healthcare are among the other significant factors contributing to the industry revenue growth.

Some Key Highlights from the Report

Hospitals segment accounted for a significantly large revenue share in 2021 and is expected to register a rapid growth rate during the forecast period owing to an increasing number of patients getting hospitalized. Hospitals also have their own diagnostic center in various areas, which also requires catheters for diagnosing and imaging-related purposes. Catheters are also used after operation to remove fluid and blood from the body. In addition, an increase in government spending on building developed healthcare infrastructure has led to increase in number of hospitals in emerging countries. Moreover, increase in the number of women suffering from Urinary Tract Infections (UTIs) has increased demand for the catheters in hospitals and is expected to drive market growth during the forecast period.

Urinary incontinence segment accounted for largest market revenue share in 2021 and is expected to register steady growth rate during the forecast period. This is owing to increasing cases of UTIs and other medical conditions such as stroke, paralysis, mobility impairment, and cancer. Urge incontinence and stress are the most common types of urinary incontinence found in women these days. Functional urinary incontinence occurs when there is a lack of mobility in reaching the bathroom in severe arthritis or bedridden cases, which is driving growth of the market.

Market in North America accounted for largest revenue share in 2021 owing to increasing awareness about UTIs, presence of highly skilled professionals, and well-established medical equipment manufacturing companies such as ConvaTec Inc., Teleflex Incorporated, and others in this region.

In February 2021, Minnesota Medical Technologies Corporation, which is a medical device manufacturing company based in Stewartville, U.S., and Wellspect Healthcare, had come into agreement for the distribution of fecal incontinence insert developed by Minnesota Medical across Europe

Top Players in the Global Urinary Catheter Market:

B. Braun Melsungen AG, Boston Scientific Corporation, Coloplast, ConvaTec Inc., Becton, Dickinson and Company, Cardinal Health, Teleflex Incorporated, Wellspect Healthcare, Medical Technologies of Georgia, and J and M urinary catheter sizes, LLC.

The coronavirus pandemic has had a drastic impact on the global healthcare industry, with rising cases of COVID-19 worldwide, substantially growing hospital admission and readmission rates, and rising demand for telehealth and telemedicine services for remote patient monitoring. Furthermore, rising focus on development of rapid COVID-19 diagnostics such as the RT-PCR test kits, increased government funding for vaccine development, stringent regulatory norms and protocols for COVID-19 safety, and increasing sales of COVID-19 safety equipment, such as N-95 masks, face shields, PPE kits, and hand sanitizers, have driven the global pharma & healthcare industry revenue growth over the recent past.

To know more about the report @ Link2

Urinary Catheter Market Segmentation:

Type Outlook (Revenue, USD Million; 2019–2030)

Coated Catheters

Uncoated Catheters

Others

End-use Outlook (Revenue, USD Million; 2019–2030)

Hospitals

Long-term Care Facilities

Others

Product Outlook (Revenue, USD Million; 2019–2030)

Indwelling Catheters

Intermittent Catheters

External Catheters

Others

Application Outlook (Revenue, USD Million; 2019–2030)

Urinary Incontinence

General Surgery

Benign Prostatic Hyperplasia (BPH)

Others

Global Urinary Catheter Market Report: Regional Segmentation

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

Mexico

Germany

U.K.

Italy

France

BENELUX

Rest of Europe

China

India

Japan

South Korea

Rest of APAC

Brazil

Rest of LATAM

Saudi Arabia

U.A.E.

South Africa

Rest of MEA

Download Summary @ https://www.reportsanddata.com/download-summary-form/2514

Global Urinary Catheter Market: Table of Contents

Chapter 1. Methodology & Sources

1.1. Market Definition

1.2. Research Scope

1.3. Methodology

1.4. Research Sources

1.4.1. Primary Sources

1.4.2. Secondary Sources

1.4.3. Paid Sources

1.5. Market Estimation Technique

Chapter 2. Executive Summary

Chapter 3. Key Insights

Chapter 4. Global Pharma & Healthcare Market Segmentation

4.1. Global Pharma & Healthcare Market COVID-19 Impact Analysis

4.2. Industrial Outlook

4.2.1. Market indicators analysis

4.2.2. Market drivers’ analysis

4.2.3. Market restraints analysis

4.3. Technological Insights

4.4. Porter’s Five Forces Analysis

4.5. Regulatory Framework

4.6. Price trend Analysis

4.7. Competitive Metric Space Analysis

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2514

Frequently Asked Questions Answered in the Report:

What is the estimated revenue growth rate of the global Urinary Catheter market over the forecast period?

What are the major factors driving the global market revenue growth?

Which are the leading manufacturers and suppliers in the global Urinary Catheter market?

Which regional market is expected to lead in terms of revenue share in the global Urinary Catheter market over the forecast years?

What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis of the market?

Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure the report is well suited to meet your requirements.

Read More Reports:

Anesthesia CO2 Absorbent Market @ https://www.biospace.com/article/anesthesia-co2-absorbent-market-growth-2022-2030-increasing-number-of-people-suffering-from-chronic-diseases-is-driving-industry-revenue/

Antiviral Drugs Market @ https://www.biospace.com/article/antiviral-drugs-market-growth-2022-2030-rising-incidence-of-influenza-respiratory-syncytial-virus-activity-and-other-viral-respiratory-infections/

Asparaginase Market @ https://www.biospace.com/article/asparaginase-market-demand-2022-2030-growth-of-pharmaceutical-and-food-industries-is-driving-industry-revenue-growth/

Biochips Market @ https://www.biospace.com/article/biochips-market-demand-2022-2030-increasing-adoption-of-biochips-for-detecting-and-testing-allergens-is-expected-to-drive-revenue-growth/

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

[blog-site-for-market-research]

Urology Devices Market Outlook, Industry Trends and Global Forecasts, 2023-2032

Market Scope

The urological devices market was valued at USD 36.5 billion in 2022 and is expected to rise from USD 37.96 billion in 2023 to USD 48.5 billion by 2032, with a compound annual growth rate (CAGR) of 4% between 2023 and 2032.

Growth Drivers and Challenges

Notable rise in the number of patients suffering from diabetes and high blood pressure (hypertension) has fostered the demand for advanced urology devices in recent years. These diseases are known for causing kidney failure. The American Kidney Fund’s recent studies show that nearly 40.4% of the overall kidney failure cases worldwide are caused by diabetes, while 30% is the result of high blood pressure. Cases of diabetes and hypertension have been surging exponentially in developing countries across Middle East and Asia Pacific, considering the prevalence of stressful and hectic lifestyle and the burgeoning elderly populace.

Another growth rendering factor can be the expanding geriatric population prone to kidney and urinary disorders. The demand for urology devices is further elevated by the mounting demand for minimally invasive procedures and surge in technical advances. Canada as well as the United States (US) are experiencing substantial rise in the number of people affected by chronic kidney and urinary disorders in conjunction with the growing prevalence of a sedentary lifestyle. On top of this, large-scale funds by governments for improving the healthcare infrastructure would also have an incredible impact on the global market.

Market Segmentation

The MRFR study has outlined various aspects of the urology devices market report for enhanced understanding, shedding light on major segments like types, applications, technology, and end users.

Different types of urology devices available in the industry are endoscopy devices, urinary incontinence & pelvic organ prolapsed devices, urinary stone treatment devices, benign prostatic hyperplasia treatment devices, dialysis equipment, and more.

Urology devices’ top applications are Prostate Cancer, Urinary Incontinence, Urinary Stones, as well as Benign Prostatic Hyperplasia. Urinary stones occur in 1 in every 20 individuals, with the major reasons being diabetes, high blood pressure, and history of kidney failure. As a result, urology devices market outlook are witnessing enormous demand for treating urinary stones, cases of which have been escalating rapidly worldwide.

Technology-wise, the segments are minimally invasive surgery, robotic surgery, and more.  

End-users listed are ambulatory services, hospitals, and more.

Regional Analysis

The urology devices industry has been regionally considered for APAC/Asia Pacific, MEA/Middle East & Africa, the Americas, and Europe.

America maintains its winning streak and will continue to do so throughout the evaluation timeframe, thanks to the escalating cases of kidney stones, traumatic injury, prostate cancer, and others. The American Urological Association Foundation confirms that benign prostatic hyperplasia (BPH), urinary incontinence (UI), urinary tract infections, and kidney and ureteral stones are the top urological ailments occurring in the region. Surge in lifestyle-based health issues, significant healthcare spending, and a well-developed healthcare system present in both Canada and the US also add to the regional market value. Favorable reimbursement structure also add to the market worth. Not only clinics and hospitals, but urology devices are increasingly being used in the domestic sector as well, as the rising number of geriatric patients prefer at-home settings.

Asia Pacific could be the fastest progressing market in the next few years, on account of the booming population with significant unmet medical needs and the surge in economic standards. Mounting cases of Benign Prostatic Hyperplasia (BPH) as well as Urinary Tract Infection (UTI) also raises the demand for urology devices. With the rising focus on replacing and upgrading the existing healthcare infrastructure, urology devices would note higher demand in the following years. Besides, majority of the players in the region are spending considerably on exhaustive research and development of the latest types of urology devices. Urology device manufacturers are also indulging in mergers and acquisitions to enhance individual as well as cumulative industry growth.

Top Companies

The top urology devices manufacturers in the market are C. R. Bard Inc. (US), Boston Scientific Corporation (US), Stryker (US), Olympus Corporation (Japan), HealthTronics, Inc (US), KARL STORZ GmbH & Co. KG (Germany), NIKKISO CO. LTD (Japan), Medtronic (US), Dornier MedTech (Germany), Fresenius Medical Care AG & Co. KGaA (Germany), Cook (US), and many more.

These contenders expend huge amounts on research and development (R&D) for product innovation as well as new launches, which helps them gain a higher share in the worldwide industry. They also use strategies such as acquisitions, FDA approvals, collaborations, expansions, and joint ventures, among others.

For instance, in May 2021, Olympus Corporation acquired Medi-Tate Ltd., an Israeli medical device firm. The acquisition is projected to bolster Olympus’s position in the urological devices market, also bolstering its product offering for the treatment of benign prostatic hyperplasia (BPH) treatment.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com Website: https://www.marketresearchfuture.com

[researchnesterinsights]

Benign Prostatic Hyperplasia Treatment Market: Global Industry Size, Growth Rate, Emerging Trends, Regional Analysis and Research Report and Forecast to 2029

Research Nester released a report titled “Benign Prostatic Hyperplasia Treatment Market: Global Demand Analysis & Opportunity Outlook 2029”which delivers detailed overview of the benign prostatic hyperplasia treatment market in terms of market segmentation by treatment type, application and region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The benign prostatic hyperplasia treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the increasing elderly population and subsequent rise in prevalence of benign prostatic hyperplasia. Additionally, the rapid rise in preference for minimal invasive surgeries for the treatment of benign prostatic hyperplasiais also likely to bolster the growth of this market. As per National Center for Biotechnology Information, clinical benign prostate hyperplasia is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms. The prevalence of benign prostate hyperplasia increases after the age of 40 years, with a prevalence of 8%-60% at age 90 years.

Get Sample Data Copy of This Report @ https://www.researchnester.com/sample-request-2946

The market is segmented by treatment type into [drug {alpha blockers (alfuzosin, doxazosin, tamsulosin, and terazosin), 5-alpha reductase inhibitors (finasteride and dutasteride),and phosphodiesterase 5 inhibitors} and surgery (TURP, TUMT, TUNA, laser, urolift therapy, prostatic stenting, rezum therapy and others)]. Among these segments, the drug treatment segment is anticipated to hold the largest share by the end of 2021 in the benign prostatic hyperplasia treatment market due to its use as a first line of treatment among men with moderate symptoms. Surgery segment is also projected to witness growth due to greater adoption of minimally invasive surgeries by patients with severe symptoms.

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which, the benign prostatic hyperplasia treatment market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period. Currently, the market in North America holds the largest share. This can be attributed to greater emphasis of institutions in the region on research and development for devising innovative treatment procedures, along with increasing elderly and obese population.

Rising prevalence of benign prostatic hyperplasia due to increase in geriatric population and Increasing preference for minimally invasive surgeries to Drive Market Growth

According to the United Nations, it is estimated that by 2050, every one in six people will be 65 years or older, i.e., 16% of the total world population. Along with this, the number of persons above 80 years or older is also projected to triple by the end of 2050.

Age is one of the most predominant risk factors for benign prostatic hyperplasia. It has been observed that men whose age is above 40 years or more possess a greater risk of having benign prostatic hyperplasia. As a consequence, the rising prevalence of benign prostatic hyperplasia in recent years is expected to boost the market growth in upcoming years. However, the limited outreach of drug treatment in terms of patients and expensive cost of surgery are some of the factors that are estimated to restrain market growth in the near future.

This report also provides the existing competitive scenario of some of the key players of the benign prostatic hyperplasia treatment market which includes company profiling of Boston Scientific Corporation (NYSE: BSX), Olympus Corporation (TYO), Abbott (NYSE: ABT), Coloplast Group (CPH), GlaxoSmithKline PLC (LON: GSK), Merck & Co. (NYSE: MRK), Eli Lilly (NYSE:LLY), Asahi Kasei Corporation (TYO), and Astellas Pharma Inc. (TYO). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the benign prostatic hyperplasia treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Get Sample Data Copy of This Report @ https://www.researchnester.com/sample-request-2946

About Research Nester:

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919